Practice Economics

Experts call for broad sharing of clinical trial data

View on the News

Data sharing will help research

Contrary to industry fears, we argue that access to full – though appropriately deidentified – data sets from clinical trials will benefit the research-based biopharmaceutical industry. We predict that it will help to increase the efficiency of drug development, improve cost-effectiveness, improve comparative-effectiveness analysis, and reduce duplication of effort among trial sponsors.

A managed-release environment that allows sharing of patient-level data while ensuring patient privacy would create a level playing field for all stakeholders. What is sometimes labeled as "free riding" may ultimately pay dividends for innovative companies and for public health. It is ironic that the organizations that most resist wider access to data are the ones that stand to benefit so much from greater transparency.

Dr. Hans-Georg Eichler, Frank Petavy, Dr. Francesco Pignatti, and Dr. Guido Rasi are all with the European Medicines Agency in London. Their remarks are taken from an accompanying editorial(N. Eng. J. Med. 2013 Oct. 21 [doi: 10.1056/NEJMp1310771]).


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Pages

Recommended Reading

What you need to know about health insurance exchanges
MDedge Rheumatology
Federal shutdown begins; health programs impacted
MDedge Rheumatology
Obamacare exchanges open for enrollment during shutdown
MDedge Rheumatology
Information technology costs rose 28% in 5 years
MDedge Rheumatology
How often do patient data end up in the wrong chart?
MDedge Rheumatology
Physician-assisted suicide
MDedge Rheumatology
ACA exchanges limp along after 2 weeks
MDedge Rheumatology
Congress approves deal to open government, leaves health reform intact
MDedge Rheumatology
Improving communication may influence outcomes, patient satisfaction
MDedge Rheumatology
Obama addresses health exchange website woes
MDedge Rheumatology